Literature DB >> 28629781

Position paper for the evaluation and management of oral status in patients with valvular disease: Groupe de Travail Valvulopathies de la Société Française de Cardiologie, Société Française de Chirurgie Orale, Société Française de Parodontologie et d'Implantologie Orale, Société Française d'Endodontie et Société de Pathologie Infectieuse de Langue Française.

Sarah Millot1, Philippe Lesclous2, Marie-Laure Colombier3, Loredana Radoi4, Clément Messeca5, Mathieu Ballanger6, Jean-Luc Charrier7, Philippe Tramba8, Stéphane Simon9, Alain Berrebi10, Fabien Doguet11, Emmanuel Lansac12, Christophe Tribouilloy13, Gilbert Habib14, Xavier Duval15, Bernard Iung16.   

Abstract

Oral health is of particular importance in patients with heart valve diseases because of the risk of infective endocarditis. Recommendations for antibiotic prophylaxis before dental procedures have been restricted, but the modalities of oral evaluation and dental care are not detailed in guidelines. Therefore, a multidisciplinary working group reviewed the literature to propose detailed approaches for the evaluation and management of buccodental status in patients with valvular disease. Simple questions asked by a non-dental specialist may draw attention to buccodental diseases. Besides clinical examination, recent imaging techniques are highly sensitive for the detection of inflammatory bone destruction directly related to oral or dental infection foci. The management of buccodental disease before cardiac valvular surgery should be adapted to the timing of the intervention. Simple therapeutic principles can be applied even before urgent intervention. Restorative dentistry and endodontic and periodontal therapy can be performed before elective valvular intervention and during the follow-up of patients at high risk of endocarditis. The detection and treatment of buccodental foci of infection should follow specific rules in patients who present with acute endocarditis. Implant placement is no longer contraindicated in patients at intermediate risk of endocarditis, and can also be performed in selected high-risk patients. The decision for implant placement should follow an analysis of general and local factors increasing the risk of implant failure. The surgical and prosthetic procedures should be performed in optimal safety conditions. It is therefore now possible to safely decrease the number of contraindicated dental procedures in patients at risk of endocarditis.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Dental implant; Endocardite infectieuse; Foyers infectieux oraux; Implant dentaire; Infective endocarditis; Oral infectious foci; Parodontopathie; Periodontitis; Valvular heart disease; Valvulopathie

Year:  2017        PMID: 28629781     DOI: 10.1016/j.acvd.2017.01.012

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  4 in total

1.  Relationship of oral conditions to the incidence of infective endocarditis in periodontitis patients with valvular heart disease: a cross-sectional study.

Authors:  Masami Ninomiya; Mari Hashimoto; Kouji Yamanouchi; Yoshiaki Fukumura; Toshihiko Nagata; Koji Naruishi
Journal:  Clin Oral Investig       Date:  2019-06-13       Impact factor: 3.573

2.  Involvement of Tunisian General Practitioners in the Management of Patients at Risk of Infective Endocarditis: A Cross-Sectional Study.

Authors:  Malek Lagha; Mehdi Khemiss; Ines Kallel; Asma Araissia; Chems Belkhir; Saida Sahtout; Sana Bagga
Journal:  Int J Dent       Date:  2021-03-24

3.  Saving patients by pulling their teeth out - but killing them softly afterwards with dental implants?

Authors:  Asbjorn Jokstad
Journal:  Clin Exp Dent Res       Date:  2018-10-26

4.  Impact of cone-beam computed tomography for the identification and management of an oral portal of entry in patients with infective endocarditis. A Delphi study.

Authors:  A Cloitre; E Hascoët; B Iung; X Duval; P Lesclous
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-01-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.